| Literature DB >> 19232964 |
Matthew D Nielsen1, Robert W Mendicino, Alan R Catanzariti.
Abstract
UNLABELLED: Lower extremity infections are a growing challenge. Moderate to severe infections are frequently polymicrobial in nature and require appropriate parenteral antibiotic therapy. Ideally, empiric treatment should be broad spectrum in coverage, simplistic in use, and economically reasonable for the patient and the health care system. This article retrospectively reviewed the outcomes of 230 patients, 159 (69.13%) of whom were diabetic, who were admitted with lower extremity infections and who were empirically treated with ertapenem. Ertapenem was well tolerated with a low adverse effect profile. We found a 79.13% rate (182 of 230 patients) of favorable outcome with this regimen, which is comparable to other published studies that have looked at the use of this agent. Ertapenem is a once-daily, broad-spectrum carbapenem antibiotic indicated for the treatment of complicated skin and skin-structure infections (cSSSI). Ertapenem is an appropriate choice for empiric antibiotic therapy of lower extremity infections. LEVEL OF CLINICAL EVIDENCE: 2.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19232964 DOI: 10.1053/j.jfas.2008.11.008
Source DB: PubMed Journal: J Foot Ankle Surg ISSN: 1067-2516 Impact factor: 1.286